Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Daratumumab, Bortezomib, Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory (RR) Multiple Myeloma (MM): Pooled Subgroup Analysis of Lepus and Castor

Blood (2020) 136 (Supplement 1): 38–41.

https://doi.org/10.1182/blood-2020-136108

Published: 2020

Journal Articles

Efficacy of Isatuximab with Pomalidomide and Dexamethasone in Elderly Patients with Relapsed/Refractory Multiple Myeloma: Icaria-MM Subgroup Analysis

Fredrik H. Schjesvold, MD PhD, Paul G. Richardson, MD, Michel Attal, MD PhD, Thierry Facon, MD, Adrián Alegre, MD, Andrew Spencer, DM, Artur Jurczyszyn, MD, Kazutaka Sunami, MD PhD, Laurent Frenzel, MD PhD, Chang-Ki Min, MD PhD, Solenn Le-Guennec, Frank Campana, MD, Helgi van de Velde, MD PhD, Samira Bensfia, MD, Sara Bringhen

Blood (2019) 134 (Supplement_1): 1893.

https://doi.org/10.1182/blood-2019-128010

Published: 2019

Journal Articles

Predictive Model of Early Relapse in Newly Diagnosed Multiple Myeloma: Analysis from a Pooled Dataset

Blood (2019) 134 (Supplement_1): 2130.

https://doi.org/10.1182/blood-2019-125640

Published: 2019

Journal Articles

MCL-1 Inhibitor-Induced Killing of Multiple Myeloma Is Modulated By the Relative Level of Expression of Pro-Survival Members of the BCL-2 Family and the Proto-Oncogene MYC

Andrew Spencer, DM, Tiffany Khong, BSc, PhD, Maoshan Chenn, PhD

Blood (2019) 134 (Supplement_1): 1825.

https://doi.org/10.1182/blood-2019-127843

Published: 2019

Journal Articles

A Longitudinal Evaluation of Euroflow and Combined Quantitative Immunoprecipitation (QIP) and Free Light Chain (FLC) Mass Spectometry (MS) in Functional High Risk Multiple Myeloma

Andrew Spencer, DM, Tiffany Khong, BSc, PhD, Flora Yuen, BBiomedSc, Hannah Victoria Giles, FRCPath, MRCP, Malgorzata Gorniak, BSc, Hang Quach, MBBS, FRACP, FRCPA, MD, Noemi Horvath, MBBS FRACP FRCPA, Ian H. Kerridge, FRACP,FRCPA,MPhil,BA, Edwin Sze-Hung Lee, MD FRACP, FRCP, FRCPA, FRCPath, Krystal Bergin, Shreerang Sridesai, MBBS, FRACP, FRCPA, Anna Kalff, MBBS, John Reynolds, PhD

Blood (2019) 134 (Supplement_1): 3090.

https://doi.org/10.1182/blood-2019-129760

Published: 2019

Journal Articles

Identification of Novel Immune Cell Populations in Lenalidomide Refractory Relapsed Multiple Myeloma Patients Treated with Pomalidomide and Low Dose Dexamethasone

Anna Kalff, MBBS, Tiffany Khong, BSc, PhD, Malarmathy Ramachandran, Sam Norton, PhD, Andrew Mitchell, PhD, John Reynolds, PhD, Hang Quach, MBBS, FRACP, FRCPA, MD, P Joy Ho, MBBS(Syd) DPhil(Oxon) FRACP FRCPA FFSc(RCPA), Noemi Horvath, MBBS FRACP FRCPA, Peter Mollee, MBBS, MMSc, FRACP, FRCPA, Nola Kennedy, Roslyn Kemp, Andrew Spencer, DM

Blood (2019) 134 (Supplement_1): 3186.

https://doi.org/10.1182/blood-2019-130154

Published: 2019

Journal Articles

Panobinostat (LBH589) in Combination with the β-Catenin Inhibitor Tegavivint (BC2059) Exerts Significant Anti-Myeloma Activity Both in Vitro and In Vivo

Ioanna Savvidou, MD, Tiffany Khong, BSc, PhD, Sophie Whish, Tara Sepehrizadeh, Sridurga Mithraprabhu, PhD MSc, Michael DeVeer, BSc, PhD, Andrew Spencer, DM

Blood (2019) 134 (Supplement_1): 5540.

https://doi.org/10.1182/blood-2019-126468

Published: 2019

Journal Articles

A Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16)

Anna Kalff, MBBS, Jake Shortt, MBBS FRACP FRCPA PhD, Flora Yuen, BBiomedSc, John Reynolds, PhD, Hang Quach, MBBS, FRACP, FRCPA, MD, Craig Thomas Wallington-Beddoe, BSc,MBBS,PhDFRACP,FRCPA, Patricia Walker, MBBS, BMedSci, FRACP, FRCPA, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Rosanne Dunn, PhD, Andrew Spencer, DM

Blood (2019) 134 (Supplement_1): 3144.

https://doi.org/10.1182/blood-2019-130084

Published: 2019

Journal Articles

MDX-1097 Binds Specifically to Kappa Myeloma Cells and Anti-Tumour Activity Is Mediated by Multiple Effector Cells.

Mae Wong, PhD, Parisa Asvadi, PhD, Rosanne Dunn, PhD, Darren Jones, Douglas Campbell, PhD, Andrew Spencer, DM

Blood (2009) 114 (22): 1846.

https://doi.org/10.1182/blood.V114.22.1846.1846

Published: 2009

Journal Articles

The Prolonged Time to Progression with Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Relapsed or Refractory Multiple Myeloma Is Unaffected by Extent of Prior Therapy or Previous Anthracycline Exposure.

Joan Blade, MD, Jesus San Miguel, MD, Arnon Nagler, MD, MSc, Pieter Sonneveld, MD, PhD, Andrew Spencer, DM, Tadeusz Robak, MD, PhD, Kathleen Hennessey, PharmD, Suneel D. Mundle, PhD, Sen H. Zhuang, MD, PhD, Jean-Luc Harousseau, MD, Robert Z. Orlowski, MD, PhD

Blood (2007) 110 (11): 410.

https://doi.org/10.1182/blood.V110.11.410.410

Published: 2007

Journal Articles

Early Normalization of Serum Free Light Chain Is Associated with Prolonged Time to Progression Following Bortezomib ± Pegylated Liposomal Doxorubicin Treatment of Relapsed/Refractory Multiple Myeloma.

Robert Orlowski, MD, PhD, Heather Sutherland, MD, PhD, Joan Bladé, MD, Jesús San Miguel, MD, Roman Hájek, MD, PhD, Arnon Nagler, MD, MSc, Pieter Sonneveld, MD, PhD, Andrew Spencer, DM, Tadeusz Robak, MD, PhD, Suneel Mundle, PhD, Donghan Luo, PhD, Sen Hong Zhuang, MD, PhD, Jean-Luc Harousseau, MD

Blood (2007) 110 (11): 2735.

https://doi.org/10.1182/blood.V110.11.2735.2735

Published: 2007

Journal Articles

Effect of Disease Stage and Time Since Diagnosis on Time to Progression for Pegylated Liposomal Doxorubicin + Bortezomib vs Bortezomib Alone in Relapsed or Refractory Multiple Myeloma.

Heather J. Sutherland, MD, PhD, Joan Blade, MD, Jesus San Miguel, MD, Arnon Nagler, MD, MSc, Pieter Sonneveld, MD, PhD, Andrew Spencer, DM, Tadeusz Robak, MD, PhD, Wane O’Neal, PharmD, Suneel D. Mundle, PhD, Sen H. Zhuang, MD, PhD, Jean-Luc Harousseau, MD, Robert Z. Orlowski, MD, PhD

Blood (2007) 110 (11): 2740.

https://doi.org/10.1182/blood.V110.11.2740.2740

Published: 2007

Journal Articles

An Outpatient Salvage Approach for Advanced Lymphoma Incorporating Stratification and Dose-Escalation.

Andrew Spencer, DM, Andrew Grigg, MBBS, John Catalano, MBBS, Michael Leahy, MBBS, Craig Underhill, MBBS, Chris Arthur, MBBS, James DRozario, MBBS, Ray Lowenthal, DM, Kerry Taylor, MBBS

Blood (2005) 106 (11): 3336.

https://doi.org/10.1182/blood.V106.11.3336.3336

Published: 2005

Journal Articles

A Stratified Risk-Adapted Approach to Lymphoma Salvage in an Outpatient Setting.

Andrew Spencer, DM, John Catalano, FRACP, Andrew Grigg, FRACP, Michael Leahy, FRACP, Craig Underhill, FRACP, Vinod Ganju, FRACP, Christopher Arthur, FRACP

Blood (2004) 104 (11): 4597.

https://doi.org/10.1182/blood.V104.11.4597.4597

Published: 2004

Journal Articles

Fluvastatin-Zometa (FluZom) as A Possible Therapeutic Approach to Plasma Cell Disorders.

Andrew Spencer, DM, Cindy Baulch-Brown, PhD, Kate Reed, BSc, Kevin Lynch, MBBS

Blood (2004) 104 (11): 4937.

https://doi.org/10.1182/blood.V104.11.4937.4937

Published: 2004

NARROW

Daratumumab, Bortezomib, Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory (RR) Multiple Myeloma (MM): Pooled Subgroup Analysis of Lepus and Castor

Efficacy of Isatuximab with Pomalidomide and Dexamethasone in Elderly Patients with Relapsed/Refractory Multiple Myeloma: Icaria-MM Subgroup Analysis

Predictive Model of Early Relapse in Newly Diagnosed Multiple Myeloma: Analysis from a Pooled Dataset

MCL-1 Inhibitor-Induced Killing of Multiple Myeloma Is Modulated By the Relative Level of Expression of Pro-Survival Members of the BCL-2 Family and the Proto-Oncogene MYC

A Longitudinal Evaluation of Euroflow and Combined Quantitative Immunoprecipitation (QIP) and Free Light Chain (FLC) Mass Spectometry (MS) in Functional High Risk Multiple Myeloma

Identification of Novel Immune Cell Populations in Lenalidomide Refractory Relapsed Multiple Myeloma Patients Treated with Pomalidomide and Low Dose Dexamethasone

Panobinostat (LBH589) in Combination with the β-Catenin Inhibitor Tegavivint (BC2059) Exerts Significant Anti-Myeloma Activity Both in Vitro and In Vivo

A Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16)

MDX-1097 Binds Specifically to Kappa Myeloma Cells and Anti-Tumour Activity Is Mediated by Multiple Effector Cells.

The Prolonged Time to Progression with Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Relapsed or Refractory Multiple Myeloma Is Unaffected by Extent of Prior Therapy or Previous Anthracycline Exposure.

Early Normalization of Serum Free Light Chain Is Associated with Prolonged Time to Progression Following Bortezomib ± Pegylated Liposomal Doxorubicin Treatment of Relapsed/Refractory Multiple Myeloma.

Effect of Disease Stage and Time Since Diagnosis on Time to Progression for Pegylated Liposomal Doxorubicin + Bortezomib vs Bortezomib Alone in Relapsed or Refractory Multiple Myeloma.

An Outpatient Salvage Approach for Advanced Lymphoma Incorporating Stratification and Dose-Escalation.

A Stratified Risk-Adapted Approach to Lymphoma Salvage in an Outpatient Setting.

Fluvastatin-Zometa (FluZom) as A Possible Therapeutic Approach to Plasma Cell Disorders.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only